| Title |
Adverse Events During Treatment of Drug-Resistant Tuberculosis: A Comparison Between Patients With or Without Human Immunodeficiency Virus Co-infection
|
|---|---|
| Published in |
Drug Safety, August 2013
|
| DOI | 10.1007/s40264-013-0091-1 |
| Pubmed ID | |
| Authors |
Evans Sagwa, Nunurai Ruswa, Jean Paul Musasa, Aukje K. Mantel-Teeuwisse |
| Abstract |
In settings such as Namibia with a high prevalence of human immunodeficiency virus (HIV) and drug-resistant (DR) tuberculosis (TB) co-infection, interactions and adverse events associated with second-line anti-TB and antiretroviral medicines pose a unique challenge in the treatment of both infections. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | <1% |
| Unknown | 108 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 21% |
| Researcher | 19 | 17% |
| Student > Ph. D. Student | 12 | 11% |
| Student > Bachelor | 10 | 9% |
| Student > Postgraduate | 7 | 6% |
| Other | 18 | 17% |
| Unknown | 20 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 39% |
| Nursing and Health Professions | 9 | 8% |
| Agricultural and Biological Sciences | 7 | 6% |
| Psychology | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 16 | 15% |
| Unknown | 25 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2013.
All research outputs
#18,343,746
of 22,716,996 outputs
Outputs from Drug Safety
#1,522
of 1,696 outputs
Outputs of similar age
#147,711
of 197,230 outputs
Outputs of similar age from Drug Safety
#12
of 13 outputs
Altmetric has tracked 22,716,996 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,696 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.